IDH1 and glioblastoma: In TMZ-receiving patients with GBM harboring wild-type IDH1 and non-G-CIMP, the combined expression of H2AFJ with PMT, TNFα-NF-κB, or IL6-STAT3 geneset exhibited an inverse correlation with time to new tumor event after the treatment (Figure 5E).